Every Form 4 that MARIMED INC (MRMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRMD filings page.
MARIMED INC. (MRMD) reported insider equity activity by Chief Operating Officer Timothy Shaw. On 2026-09-01, 65,000 Restricted Stock Units converted on a one-for-one basis into common stock. Of these, 22,523 shares of common stock were withheld at $0.0816 per share to satisfy tax withholding obligations, with the remaining shares effectively delivered to Shaw. Separately, 2,000,000 common shares are reported as held indirectly by the Shaw Family Trust for his children; the trust is irrevocable, Shaw’s spouse is trustee, and Shaw disclaims beneficial ownership of those securities.
MARIMED INC. President and CEO Jon R. Levine reported on July 15, 2026 the vesting and settlement of 30,625 restricted stock units into common stock and a related 10,612-share tax-withholding disposition. Following these transactions, he directly holds 21,358,631 common shares, with 91,875 RSUs remaining under the grant that will vest in three equal installments on October 15, 2026, January 15, 2027 and April 15, 2027. An additional 6,684,640 shares are held in a family trust for his spouse and children, for which he disclaims beneficial ownership.
MariMed Inc. reports that COO Timothy Shaw exercised 42,656 RSUs into common stock and had 14,781 shares withheld to satisfy tax obligations related to the vesting. After these transactions, he holds 9,412,123 shares directly and 127,969 RSUs, plus 2,000,000 shares held in an irrevocable family trust for his children, for which he disclaims beneficial ownership.
MARIMED INC. Chief Commercial Officer Ryan Crandall reported RSU vesting and related tax withholding on July 15, 2026. He converted 32,813 Restricted Stock Units into common stock and had 11,370 shares withheld to cover taxes, leaving 1,124,246 common shares and 98,437 RSUs held directly. Remaining RSUs vest in three equal installments through April 15, 2027, and the transactions were not made under a Rule 10b5-1 plan.
MariMed Inc. chief financial officer Mario Pinho reported equity-compensation transactions dated July 15, 2026. He exercised 88,276 restricted stock units into common stock and had 30,589 common shares withheld at $0.0662 per share to satisfy tax withholding obligations. After these transactions, he directly holds 335,172 common shares and continues to hold unvested RSUs from grants dated July 15, 2024 and April 15, 2026 that vest in installments through April 15, 2027.
MARIMED INC. director Eva M.D. Selhub received an equity award of 173,077 Restricted Stock Units on July 15, 2026 as part of her board fees. The RSUs vested immediately and converted one-for-one into 173,077 common shares, after which she directly owns 730,748 common shares.
MARIMED INC. director Allen David R received 192,308 Restricted Stock Units on July 15, 2026 in lieu of a portion of his board fees. The RSUs vested upon grant and converted one-for-one into 192,308 shares of common stock at no cash exercise price, increasing his direct holdings to 743,452 shares. No RSUs from this award remain outstanding.
MariMed Inc. director Edward J. Gildea received 192,308 restricted stock units on July 15, 2026 as part of his board fees, granted in lieu of cash. These RSUs vested immediately and converted one-for-one into 192,308 common shares at no cash cost, increasing his direct holdings to 1,172,516 shares and leaving no RSUs outstanding from this award.
MariMed Inc. reports that Chief Commercial Officer Ryan Crandall exercised 250,000 Restricted Stock Units into common stock on June 15, 2026, from a December 15, 2025 RSU grant. To cover tax obligations, 86,626 shares were withheld at $0.069 per share. Following these transactions, he directly holds 1,102,803 common shares, with remaining RSUs under this grant scheduled to vest in equal installments on December 15, 2026, June 15, 2027 and December 15, 2027.
MARIMED INC. director Eva Selhub, M.D. exercised 75,000 Restricted Stock Units (RSUs) into the same number of shares of common stock. This was recorded as a derivative exercise, not an open‑market purchase or sale. After the transaction, she directly holds 557,671 shares of common stock. The RSUs converted to common stock on a one-for-one basis and this grant, originally awarded on June 12, 2025, is now fully exhausted under its award agreement.
MariMed Inc. director Edward J. Gildea exercised restricted stock units into common shares. On June 12, 2026, 75,000 RSUs converted into 75,000 shares of common stock on a one-for-one basis at no cash exercise price. This exhausted the June 12, 2025 RSU grant, and Gildea now holds 980,208 common shares directly.
MARIMED INC. director David R. Allen exercised restricted stock units into common shares. He converted 75,000 RSUs into 75,000 shares of common stock at a stated price of $0.0000 per share. After this transaction, he holds 551,144 common shares directly. The RSUs were originally granted on June 12, 2025 and have now been fully settled, with no units remaining under that grant.
MariMed Inc. Chief Commercial Officer Ryan Crandall reported compensation-related equity activity. He exercised 54,000 Restricted Stock Units (RSUs), which converted into an equal number of common shares. In connection with this vesting, 18,711 common shares were withheld by MariMed to cover tax obligations, rather than sold on the open market. Following these transactions, Crandall directly holds 939,429 shares of MariMed common stock, reflecting a routine RSU vesting and associated tax-withholding disposition.
Gildea Edward J reported acquisition or exercise transactions in this Form 4 filing.
MariMed Inc. director Edward J. Gildea reported new equity compensation. On June 4, 2026, he was granted 75,000 Restricted Stock Units (RSUs), each convertible into one share of common stock. The RSUs vest in full one year from the grant date. Following this filing, he directly holds 905,208 shares of common stock and a separate award of 75,000 RSUs.
MariMed Inc. director Allen David R reported a new equity award rather than an open-market trade. On June 4, he received 75,000 Restricted Stock Units (RSUs), which each convert into one share of common stock on a one-for-one basis.
The RSUs will vest in full one year from the grant date under his award agreement. After this filing, he directly holds 476,144 shares of common stock and a separate position of 75,000 RSUs, highlighting a compensation-related grant instead of a buy or sell in the market.
MARIMED INC. director Eva Selhub, M.D. reported a compensation-related equity award. She received 75,000 Restricted Stock Units (RSUs), which are a form of stock-based compensation, at a grant price of $0.00 per unit.
According to the footnotes, these RSUs convert into common stock on a one-for-one basis and will vest in full one year from the grant date, based on the award agreement between the company and Selhub. The filing also shows she directly holds 482,671 shares of common stock following the reported transactions. This Form 4 reflects an equity grant rather than any open-market share purchase or sale.
MariMed Inc. Chief Operating Officer Timothy Shaw reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised RSUs to acquire 40,625 shares of common stock, which convert on a one-for-one basis, and 14,077 shares were withheld by the company to cover tax obligations at a value of $0.0805 per share. After these transactions, Shaw holds 9,384,248 shares of common stock directly. An additional 2,000,000 shares are held by the Shaw Family Trust for the benefit of his children, and he disclaims beneficial ownership of those securities. Following this vesting event, 121,875 RSUs from the November 29, 2024 grant remain outstanding and are scheduled to vest in three equal installments on November 29, 2026, May 29, 2027, and November 29, 2027, subject to the award agreement.
MARIMED INC. President and CEO Jon R. Levine reported equity compensation activity involving company common stock and restricted stock units. He exercised 46,875 RSUs into an equal number of common shares, and 16,243 shares were withheld by the company to cover tax obligations related to this vesting.
Following these transactions, Levine directly held 21,338,618 shares of common stock. An additional 6,684,640 shares are held by the Jon Levine Family Trust for the benefit of his spouse and children, for which he disclaims beneficial ownership. After this vesting, 140,625 RSUs from the November 29, 2024 grant remain outstanding, scheduled to vest in three equal installments on November 29, 2026, May 29, 2027 and November 29, 2027.
MARIMED INC. Chief Commercial Officer Ryan Crandall reported routine equity compensation activity involving restricted stock units. On May 29, 2026, RSUs converted into 37,500 shares of common stock on a one-for-one basis, increasing his direct holdings to 917,134 shares.
To cover tax obligations from this vesting, 12,994 shares of common stock were withheld by the company at a price of $0.0805 per share. Following the transaction, Crandall also held 112,500 unvested RSUs that are scheduled to vest in three equal installments on November 29, 2026, May 29, 2027, and November 29, 2027, under an existing award agreement.
MariMed Inc. President and CEO Jon R. Levine reported open-market purchases of 60,000 shares of common stock on May 22, 2026. The buys were executed at prices of $0.0745, $0.0750, and $0.0767 per share. Following these purchases, he directly owns 21,307,986 common shares.
An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children. Levine disclaims beneficial ownership of the trust-held shares, meaning they are attributed to the trust rather than to him personally.
MariMed Inc. President and CEO Jon R. Levine reported an open-market purchase of 40,000 shares of common stock at $0.075 per share. Following this trade, he owns 21,247,986 shares directly. A separate 6,684,640 shares are held by the Jon Levine Family Trust for his spouse and children, which he disclaims as beneficially owned.
MariMed Inc. President and CEO Jon R. Levine reported routine equity compensation activity involving restricted stock units. On May 7, 2026, RSUs converted into 75,000 shares of common stock. To cover tax obligations tied to this vesting, the issuer withheld 25,988 shares, a tax-withholding disposition rather than an open-market sale.
Following these transactions, Levine directly holds 21,207,986 shares of MariMed common stock. A separate family trust holds 6,684,640 shares for the benefit of his spouse and children, and he disclaims beneficial ownership of those trust-held securities.
MariMed Inc. Chief Operating Officer Timothy Shaw received a grant of 170,625 Restricted Stock Units (RSUs). The RSUs convert to common stock on a one-for-one basis and vest in four equal installments on July 15, 2026, October 15, 2026, January 15, 2027 and April 15, 2027.
After this award, Shaw reports 9,357,700 shares of MariMed common stock held directly, plus 170,625 RSUs. An additional 2,000,000 shares are held indirectly by the Shaw Family Trust for his children, for which he disclaims beneficial ownership.
MARIMED INC. Chief Commercial Officer Ryan Crandall reported receiving a grant of 131,250 Restricted Stock Units (RSUs), each representing one share of common stock. The RSUs were awarded at a price of $0.00 per unit as equity compensation.
The RSUs convert to common stock on a one-for-one basis and will vest in four equal installments on July 15, 2026, October 15, 2026, January 15, 2027, and April 15, 2027. Following this grant, Crandall directly holds 879,634 shares of common stock and 131,250 RSUs.
MariMed Inc. Chief Financial Officer Mario Pinho received a grant of 153,125 Restricted Stock Units (RSUs) on April 15, 2026. The RSUs convert into common stock on a one-for-one basis. They vest in four equal installments on July 15, 2026, October 15, 2026, January 15, 2027 and April 15, 2027.
Following these transactions, Pinho directly holds 277,485 shares of MariMed common stock, alongside the new RSU award, reflecting his updated equity-based compensation and ownership position.
Levine Jon R reported acquisition or exercise transactions in this Form 4 filing.
MariMed Inc. President and CEO Jon R. Levine received a grant of 122,500 Restricted Stock Units (RSUs), each convertible into one share of common stock. The RSUs will vest in four equal installments on July 15, 2026, October 15, 2026, January 15, 2027, and April 15, 2027. After this grant, he holds 21,158,974 shares of common stock directly, and 6,684,640 additional shares are held by the Jon Levine Family Trust for the benefit of his spouse and children, for which he disclaims beneficial ownership.
MariMed Inc. Chief Operating Officer Timothy Shaw exercised restricted stock units into common stock. On April 2, 2026, 9,982 RSUs converted to 9,982 shares of common stock on a one-for-one basis, increasing his direct holdings.
Of these shares, 3,459 were withheld by MariMed to cover tax withholding obligations, leaving Shaw with 9,357,700 shares of common stock held directly. Separately, 2,000,000 shares are held indirectly by the Shaw Family Trust for the benefit of his children, and he disclaims beneficial ownership of those securities. The RSU grant continues, with 9,981 RSUs scheduled to vest on October 2, 2026, and 9,982 RSUs on April 2, 2027.
MariMed Inc. President and CEO Jon R. Levine reported routine equity compensation activity. On April 2, 2026 he exercised 11,518 Restricted Stock Units, receiving the same number of common shares at no cash cost as the RSUs convert one-for-one into stock.
To cover tax obligations tied to this vesting, 3,992 common shares were withheld by MariMed at a price of $0.0691 per share, leaving Levine with a net increase of 7,526 shares. After these transactions, he directly holds 21,158,974 common shares.
The filing also notes 6,684,640 common shares held by the Jon Levine Family Trust for the benefit of his spouse and children; Levine disclaims beneficial ownership of these trust shares. The RSUs were granted on April 2, 2024, with the remaining units scheduled to vest in equal installments on October 2, 2026 and April 2, 2027.
MariMed Inc. Chief Commercial Officer Ryan Crandall exercised vested equity awards and settled taxes in shares. On March 28, 2026, he converted 6,047 Restricted Stock Units (RSUs) into the same number of common shares at an exercise price of $0.00 per share.
Of these shares, 2,096 common shares were withheld by MariMed at a value of $0.0758 per share to satisfy tax withholding obligations, with the remainder added to his holdings. Following these transactions, Crandall directly held 879,634 shares of common stock. The RSUs originated from a March 28, 2024 grant, with an additional 6,046 RSUs scheduled to vest on September 28, 2026 and 6,047 RSUs on March 28, 2027.
MARIMED INC. Chief Operating Officer Timothy Shaw exercised 21,667 restricted stock units into an equal number of common shares on March 7, 2026, at a stated price of $0.00 per share. These RSUs were originally granted on March 7, 2023 and are now fully vested with no remaining units under that grant.
To cover tax withholding from this vesting, 7,508 common shares were withheld at $0.084 per share, reducing his directly held common stock to 9,351,177 shares. Separately, 2,000,000 common shares are held indirectly by the Shaw Family Trust for the benefit of his children; his spouse serves as trustee, and he disclaims beneficial ownership of those trust shares.
MariMed Inc. President and CEO Jon R. Levine reported equity compensation activity involving restricted stock units and common shares. He exercised 23,333 restricted stock units into 23,333 shares of common stock at a stated price of $0.0000 per share, reflecting a derivative exercise/conversion.
To cover tax withholding obligations from this RSU vesting, 8,085 common shares were withheld at $0.0840 per share, leaving him with 21,151,448 shares of common stock held directly after these transactions. An additional 6,684,640 common shares are held indirectly by the Jon Levine Family Trust for the benefit of his spouse and children, and he disclaims beneficial ownership of those trust-held securities.
MariMed Inc. Chief Commercial Officer Ryan Crandall reported equity compensation activity involving restricted stock units (RSUs) that convert to common shares on a one-for-one basis. On the reported date, 12,500 RSUs were exercised into 12,500 shares of common stock at no cash exercise price.
To satisfy tax withholding obligations tied to this RSU vesting, 4,332 common shares were withheld by the company. After these transactions, Crandall’s direct ownership in MariMed common stock stood at 875,683 shares.
MARIMED INC. Chief Operating Officer Timothy Shaw reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 1, 2026, 65,000 RSUs were exercised, converting on a one-for-one basis into 65,000 shares of common stock at a stated price of $0.0000 per share.
To cover tax withholding obligations tied to this RSU vesting, 22,523 shares of common stock were withheld by the company at $0.0848 per share, reducing the net shares retained. After these transactions, Shaw directly held 9,337,018 shares of MARIMED common stock.
The filing also notes 2,000,000 shares of common stock held indirectly by the Shaw Family Trust. Shaw’s spouse is the trustee, and the trust benefits their children; Shaw disclaims beneficial ownership of these trust-held securities. The RSUs involved were granted on September 1, 2023, with remaining units scheduled to vest on September 1, 2026 under an award agreement.
Marimed Inc. Chief Financial Officer Mario Pinho reported the vesting and exercise of 49,995 Restricted Stock Units, converting on a one-for-one basis into the same number of common shares at $0.00 per share on January 15, 2026. The issuer withheld 17,324 shares of common stock to satisfy tax withholding obligations related to this vesting. Following these transactions, Pinho directly holds 277,485 shares of Marimed common stock. The remaining RSUs from this July 15, 2024 grant are scheduled to vest in three equal installments on July 15, 2026, January 15, 2027 and July 15, 2027.
Mario Pinho, Chief Financial Officer of MariMed Inc., exercised 53,571 Restricted Stock Units into an equal number of common shares on 2025-12-31. 15,724 shares of common stock were withheld by the company at $0.0891 per share to cover tax obligations, and he now holds 244,814 common shares directly. These RSUs were granted on February 18, 2025 and are fully vested, with no unvested RSUs remaining under this grant.
MariMed Inc. director Eva Selhub reported an equity compensation transaction involving restricted stock units (RSUs). On December 15, 2025, 166,985 RSUs converted into the same number of shares of MariMed common stock at a stated price of $0, reflecting the non-cash nature of the award. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 under an award agreement between MariMed and Selhub. According to the filing, these RSUs were granted in lieu of cash for a portion of her fees for serving on the Board of Directors, and she beneficially owned 482,671 shares of common stock directly after the transaction.
MariMed Inc.'s Chief Financial Officer, Mario Pinho, reported equity award activity involving restricted stock units (RSUs) and common shares. On December 15, 2025, 16,075 RSUs were converted into the same number of shares of common stock at a stated price of $0, reflecting the vesting of a stock-based award.
To cover tax withholding obligations from this vesting, 4,719 shares of common stock were withheld by MariMed at a price of $0.1071 per share. After these transactions, Pinho directly owned 206,967 shares of MariMed common stock. All RSUs from the May 9, 2025 grant are now fully vested, with no unvested units remaining under that award.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported insider equity activity dated 12/15/2025. On that date, 89,859 restricted stock units vested and converted one-for-one into shares of common stock at a stated price of $0, increasing his direct holdings.
To satisfy related tax withholding obligations, 26,374 shares of common stock were withheld by MariMed at $0.1071 per share. Following these entries, Levine directly holds 21,136,200 MariMed common shares and has indirect beneficial ownership of 6,684,640 shares held by the Jon Levine Family Trust for the benefit of his spouse and children, which he formally disclaims for Section 16 purposes.
MariMed Inc. director Edward Gildea reported the conversion of restricted stock units into common stock. On December 15, 2025, 247,385 restricted stock units were settled into 247,385 shares of MariMed common stock at a stated price of $0 per share under transaction code M.
After this transaction, Gildea directly owned 905,208 shares of MariMed common stock. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 as payment in stock instead of cash for a portion of his fees for serving on the company’s board of directors.
MariMed Inc.'s Chief Commercial Officer Ryan Crandall reported stock-based compensation and related share movements dated December 15, 2025. He converted previously granted restricted stock units (RSUs) into 62,902 shares of common stock at a stated price of $0, and 18,462 shares were withheld to cover tax obligations, leaving him with 867,515 common shares held directly after the transactions.
On the same date, Crandall received a new grant of 1,000,000 RSUs, each convertible into one share of MariMed common stock. These RSUs were issued in lieu of a cash salary increase tied to his promotion to Chief Commercial Officer and will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027 and December 15, 2027.
MariMed Inc. director David R. Allen reported the conversion of restricted stock units into 176,389 shares of common stock on December 15, 2025. The transaction is shown as an acquisition at a price of $0, reflecting the settlement of equity awards rather than a cash purchase.
After this transaction, Allen directly beneficially owns 476,144 shares of MariMed common stock. The RSUs converted on a one-for-one basis, were granted on December 5, 2025, and vested in full on December 15, 2025. They were granted in lieu of cash as payment for a portion of his fees for serving on MariMed’s board of directors.
MariMed Inc.'s Chief Operating Officer Timothy Shaw reported recent stock transactions. On December 12, 2025 he purchased 45,455 shares of common stock at $0.1071 per share. On December 15, 2025, 81,772 restricted stock units vested and converted into common shares, and 24,001 shares were withheld by the company to satisfy tax withholding obligations at $0.1071 per share.
After these transactions, he directly beneficially owned 9,294,541 shares of MariMed common stock. An additional 2,000,000 shares are held indirectly through the Shaw Family Trust for the benefit of his children, for which he disclaims beneficial ownership, and no restricted stock units remain unvested under the May 23, 2025 grant.
MariMed Inc.'s Chief Commercial Officer reported routine equity compensation activity. On 12/08/2025, 54,000 restricted stock units (RSUs) converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held shares to 838,925.
On the same date, 15,850 shares of common stock were withheld by MariMed at a price of $0.0824 per share to cover tax obligations related to the RSU vesting, leaving the officer with 823,075 shares held directly after these transactions. The RSUs convert to common stock on a one-for-one basis.
The filing notes that these RSUs were originally granted on June 8, 2023, and that the remaining 54,000 RSUs from this grant are scheduled to vest on June 8, 2026, under an award agreement between MariMed and the reporting officer.
MariMed Inc. director equity compensation update: Director Edward Gildea reported receiving 247,385 restricted stock units (RSUs) of MariMed Inc. common stock on December 5, 2025. These RSUs convert to common shares on a one-for-one basis and are scheduled to vest in full on December 15, 2025 under the terms of his award agreement with the company. The filing states that the RSUs were granted in lieu of cash for a portion of his fees for serving on the Board of Directors. Following this grant, Gildea is shown as beneficially owning 657,823 shares of MariMed common stock directly, and 247,385 derivative securities in the form of RSUs.
MariMed Inc. director David R. Allen reported an equity compensation grant in the form of restricted stock units (RSUs). On December 5, 2025, he received 176,389 RSUs, each of which converts into one share of MariMed common stock on a one-for-one basis. These RSUs were granted in lieu of cash for a portion of his fees for serving on the company’s Board of Directors.
The RSUs vest in full on December 15, 2025, according to the award agreement between MariMed and Allen. After this grant, he directly beneficially owned 299,755 shares of MariMed common stock and 176,389 RSUs, all held directly.
MariMed Inc. director reports new stock-based compensation grant
A MariMed Inc. (MRMD) director filed a Form 4 disclosing an award of 166,985 restricted stock units (RSUs) on December 5, 2025. Each RSU converts into one share of MariMed common stock, and the award vests in full on December 15, 2025 under the terms of the award agreement. The RSUs were granted in lieu of cash for a portion of the director’s board fees, meaning the director chose to receive equity instead of part of the normal cash compensation. Following this grant, the director reports 315,686 shares of common stock held directly and 166,985 RSUs directly beneficially owned. This filing highlights ongoing use of equity-based compensation to align director pay with company performance.
MariMed Inc. (MRMD) reported an insider equity transaction by its Chief Commercial Officer, Ryan Crandall. On 11/29/2025, Crandall exercised 75,000 restricted stock units (RSUs), which converted into an equal number of common shares at an exercise price of $0 per share. RSUs are a form of stock-based compensation that turn into common stock as they vest.
To cover tax withholding tied to this vesting, 22,013 common shares were withheld at a price of $0.0896 per share. After these transactions, Crandall beneficially owned 784,925 shares of MariMed common stock directly. The RSUs exercised came from a grant originally made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027 and November 29, 2027.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported equity transactions dated 11/29/2025. He exercised 93,750 restricted stock units (RSUs), which converted into the same number of common shares at an exercise price of $0, and then had 27,516 shares of common stock withheld at $0.0896 per share to cover tax obligations related to the RSU vesting.
After these transactions, Levine directly beneficially owns 21,072,715 shares of MariMed common stock and has an additional 6,684,640 shares held indirectly through the Jon Levine Family Trust, for which he disclaims beneficial ownership. He also continues to hold 187,500 RSUs, from a grant made on November 29, 2024, that are scheduled to vest in four equal installments between May 29, 2026 and November 29, 2027.
MariMed Inc. Chief Operating Officer Timothy Shaw reported equity transactions involving company stock. On 11/29/2025, 81,250 restricted stock units (RSUs) converted into the same number of MariMed common shares at an exercise price of $0, increasing his directly held shares. On the same date, 23,847 common shares were withheld by MariMed at a price of $0.0896 per share to cover tax obligations tied to the RSU vesting. After these transactions, Shaw directly owned 9,191,315 shares of common stock.
In addition, 2,000,000 MariMed shares are held indirectly through the Shaw Family Trust, an irrevocable trust for his children, for which his spouse is trustee and as to which he disclaims beneficial ownership. The RSUs that vested on November 29, 2025 were part of a grant made on November 29, 2024, with the remaining RSUs from that grant scheduled to vest in four equal installments on May 29, 2026, November 29, 2026, May 29, 2027, and November 29, 2027.
MariMed (MRMD) President & CEO Jon R. Levine reported equity award activity. On November 7, 2025, 75,000 RSUs converted into common stock (Code M) at $0, and 22,013 shares were withheld to satisfy taxes (Code F) at $0.097.
Following these transactions, he holds 21,006,481 shares directly and 6,684,640 shares indirectly by the Jon Levine Family Trust. 150,000 RSUs remain outstanding, scheduled to vest in equal installments on May 7, 2026 and November 7, 2026.